Results 191 to 200 of about 236,112 (356)

Small Guanosine Triphospatase RhoA and Rho-Associated Kinase as Regulators of Trophoblast Migration [PDF]

open access: bronze, 2002
Shigetatsu Shiokawa   +9 more
openalex   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

A Homogeneous Bioluminescent System to Monitor Cyclic Guanosine Monophosphate

open access: hybrid, 2023
Nathan H. Murray   +6 more
openalex   +1 more source

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

open access: yesESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori   +9 more
wiley   +1 more source

Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo‐controlled, crossover trial

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Aims Heart failure with preserved ejection fraction (HFpEF) is a major healthcare burden with limited treatment options. Geranylgeranylacetone (GGA) has been shown to improve myocardial compliance and endothelial function in preclinical models.
Soufiane Nassiri   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy